8-KEarnings & ResultsRegulation FDExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Jan 12, 2026)

Filed January 12, 2026For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on January 12, 2026, to disclose their participation in the 44th Annual J.P. Morgan Healthcare Conference. The primary purpose of this filing is to furnish the presentation materials that management will use during their discussion of the Company's strategy, performance, and current market trends. While this filing does not contain new financial results or operational updates, investors should note that the accompanying presentation materials (Exhibit 99.1) are incorporated by reference. These materials may contain forward-looking statements regarding management's current outlook, projections, and expectations. Investors are cautioned to review these statements alongside the risks and uncertainties detailed in Quest Diagnostics' other SEC filings, including their most recent 10-K and 10-Q reports, as actual results could materially differ.

Key Highlights

  • 1Quest Diagnostics (DGX) is presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
  • 2The 8-K filing incorporates by reference the presentation materials (Exhibit 99.1) used at the conference.
  • 3The presentation will cover the Company's strategy, performance, and market developments/trends.
  • 4This filing is primarily for informational purposes regarding the conference presentation.
  • 5Forward-looking statements within the presentation materials are subject to risks and uncertainties.
  • 6Investors are advised to consult other SEC filings for a comprehensive understanding of risks and potential impacts on future results.

Frequently Asked Questions

The main purpose of this 8-K filing is to inform investors that Quest Diagnostics is participating in the 44th Annual J.P. Morgan Healthcare Conference and to furnish the presentation materials that will be used during their session.

No, this 8-K filing itself does not contain specific financial results or detailed operational updates. It serves to incorporate by reference the presentation materials which may include forward-looking statements about strategy and performance.

The presentation materials that Quest Diagnostics will use at the J.P. Morgan Healthcare Conference are furnished as Exhibit 99.1 to this 8-K filing and are incorporated by reference.

Investors should be aware that the presentation materials may contain forward-looking statements. These statements reflect management's current beliefs and projections but involve risks and uncertainties that could cause actual results to differ materially. It is recommended to review these statements in conjunction with the risk factors detailed in Quest Diagnostics' other SEC filings (10-K, 10-Q).